熱門資訊> 正文
奥本海默（Oppenheimer）以跑赢大盘开始ArriVent BioPharma
2024-07-23 03:11
- Oppenheimer started coverage of ArriVent BioPharma (NASDAQ:AVBP) with an outperform rating, citing its drug candidate firmonertinib for the treatment of EGFR-mutant non-small cell lung cancer, or NSCLC.
- The investment bank said it sees the potential US market opportunity for the drug as greater than $1.5B. It added that it believes the drug has the potential to be best-in-class, with the only other approved option being Johnson & Johnson’s (JNJ) Rybrevant.
- Oppenheimer said ArriVent’s (AVBP) balance sheet of $317M after Q1 should support operations past a pivotal study readout for firmonertinib, which is expected in the second half of 2025.
- Oppenheimer set its price target for the stock at $35.
- ArriVent (AVBP) held its initial public offering in late January.
More on ArriVent BioPharma, Inc.
- IPO Roundup: Lineage, OneStream Software, and more
- Historical earnings data for ArriVent BioPharma, Inc.
- Financial information for ArriVent BioPharma, Inc.
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
